GenSight Biologics is a privately owned biopharmaceutical company that uses innovative approaches to prevent retinal degeneration and restore vision in patients suffering from retinal diseases. They focus on ophthalmology and use two core technology platforms, the Mitochondrial Targeting Sequence and optogenetics, to develop product candidates such as LUMEVOQ and GS010. GS010 is currently in Phase III trials for Leber’s Hereditary Optic Neuropathy, a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Their gene therapy-based approach is designed to offer patients a sustainable functional visual recovery through a single treatment to each eye by intravitreal injection.